Oncología médica

2023

1. A Phase 1/2A trial of idroxioleic acid: first-in-class sphingolipid regulator and glioma cell autophagy inducer with antitumor activity in refractory glioma

   British Journal of Cancer, Vol. 129, Núm. 5, pp. 811-818

2. A rare, life-threatening debut of pancreatic adenocarcinoma: Pulmonary tumor thrombotic microangiopathy

   CURRENT PROBLEMS IN CANCER: CASE REPORTS, Vol. 10

3. Abdominal Trauma

   Radiologia, Vol. 65, pp. S32-S41

4. Atezolizumab Combined With Bevacizumab and Platinum-Based Therapy for Platinum-Sensitive Ovarian Cancer: Placebo-Controlled Randomized Phase III ATALANTE/ENGOT-ov29 Trial

   Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 41, Núm. 30, pp. 4768-4778

5. Author Correction: BIM and mTOR expression levels predict outcome to erlotinib in EGFR-mutant non-small-cell lung cancer (Scientific Reports, (2015), 5, 1, (17499), 10.1038/srep17499)

   Scientific Reports

6. Current professional standing of young medical oncologists in Spain: a nationwide survey by the Spanish Society of Medical Oncology + MIR section

   Clinical and Translational Oncology, Vol. 25, Núm. 3, pp. 796-802

7. Differences in Quality of Life and Emotional Well-being in Breast, Colon, and Lung Cancer Patients During Outpatient Adjuvant Chemotherapy: A Longitudinal Study

   Cancer Nursing, Vol. 46, Núm. 2, pp. E99-E109

8. Early Detection of Brain Metastases in a Supervised Exercise Program for Patients with Advanced Breast Cancer: A Case Report

   Medicine and science in sports and exercise, Vol. 55, Núm. 10, pp. 1745-1749

9. Functional Engagement of the PD-1/PD-L1 Complex But Not PD-L1 Expression Is Highly Predictive of Patient Response to Immunotherapy in Non-Small-Cell Lung Cancer

   Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 41, Núm. 14, pp. 2561-2570

10. Genotype-first approach to identify associations between CDH1 germline variants and cancer phenotypes: a multicentre study by the European Reference Network on Genetic Tumour Risk Syndromes

    The Lancet. Oncology, Vol. 24, Núm. 1, pp. 91-106

11. Germline heterozygous exons 8–11 pathogenic BARD1 gene deletion reported for the first time in a family with suspicion of a hereditary colorectal cancer syndrome: more than an incidental finding?

    Hereditary Cancer in Clinical Practice, Vol. 21, Núm. 1

12. Identification of fatty acid amide hydrolase as a metastasis suppressor in breast cancer

    Nature Communications, Vol. 14, Núm. 1

13. Immunogenicity of COVID-19 vaccines in lung cancer patients

    Lung Cancer, Vol. 184

14. Long-term outcomes of high-risk HR-positive and HER2-negative early breast cancer patients from GEICAM adjuvant studies and El Álamo IV registry

    Breast Cancer Research and Treatment, Vol. 201, Núm. 2, pp. 151-159

15. Molecular Results and Potential Biomarkers Identified from the Phase 3 MILO/ENGOT-ov11 Study of Binimetinib versus Physician Choice of Chemotherapy in Recurrent Low-Grade Serous Ovarian Cancer

    Clinical Cancer Research, Vol. 29, Núm. 20, pp. 4068-4075

16. Multi-omics Characterization of Response to PD-1 Inhibitors in Advanced Melanoma

    Cancers, Vol. 15, Núm. 17

17. Narrative Review of Multidisciplinary Management of Central Nervous Involvement in Patients with HER2-Positive Metastatic Breast Cancer: Focus on Elderly Patients

    Advances in Therapy, Vol. 40, Núm. 8, pp. 3304-3331

18. Nurse-Supervised Exercise for People with Stage IV Cancer: The EFICANCER Randomized Clinical Trial

    Seminars in Oncology Nursing, Vol. 39, Núm. 4

19. Perioperative Nivolumab and Chemotherapy in Stage III Non-Small-Cell Lung Cancer

    New England Journal of Medicine, Vol. 389, Núm. 6, pp. 504-513

20. Prediction of significant coronary artery disease in acute chest pain without infarction in emergency department: MAPAC Cardio-PreTest model

    European Journal of Emergency Medicine, Vol. 30, Núm. 1, pp. 40-46